Timber Pharmaceuticals Inc News - TMBR

Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split

BASKING RIDGE, NJ, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE...

Current Report Filing (8-k)

0001504167 false 0001504167 2022-11-03 2022-11-03 iso4217:USD xbrli:shares...

Timber Pharmaceuticals Announces Halt of Common Stock Trading

Compliance with NYSE Listing Requirements Contingent on Stockholder Approval of Reverse Stock Split at Special...

Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Timber Pharmaceuticals (TMBR)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB – Research Report) and Timber...

Current Report Filing (8-k)

0001504167false00015041672022-10-252022-10-25J UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM...

Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis

- Regulatory Milestones Improve Path to Filing a European Marketing Authorization Application -- Company Plans...

Current Report Filing (8-k)

0001504167false--12-3100015041672022-10-032022-10-03J UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM...

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Filed Pursuant to Rule 424(b)(5) Registration No. 333-255743 PROSPECTUS...

Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering

BASKING RIDGE, NJ, Oct. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc...

Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis

European Commission expected to issue its decision on orphan designation in approximately 30 days BASKING...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Timber Pharmaceuticals Inc (TMBR)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

TMBR News

Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split

Current Report Filing (8-k)

Timber Pharmaceuticals Announces Halt of Common Stock Trading

Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Timber Pharmaceuticals (TMBR)

Current Report Filing (8-k)

Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis

Current Report Filing (8-k)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering

Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis

Current Report Filing (8-k)

Current Report Filing (8-k)

Current Report Filing (8-k)

Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency

Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress

TMBR Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Timber Pharmaceuticals Inc (TMBR) News

Timber Pharmaceuticals Inc (TMBR)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

TMBR News

Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split

Current Report Filing (8-k)

Timber Pharmaceuticals Announces Halt of Common Stock Trading

Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Timber Pharmaceuticals (TMBR)

Current Report Filing (8-k)

Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis

Current Report Filing (8-k)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering

Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis

Current Report Filing (8-k)

Current Report Filing (8-k)

Current Report Filing (8-k)

Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency

Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress

TMBR Discussion

Your Recent History